Parasite-induced lipoxin A4 is an endogenous regulator of IL-12 production and immunopathology in Toxoplasma gondii infection

Journal of Experimental Medicine

Volumn 196, Issue 9, 2002, Pages 1253-1262

  Aliberti, Julio ^a   Serhan, Charles ^b   Sher, Alan ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Eicosanoid; Interleukin 12; Lipoxin A4; Lipoxygenase; Toxoplasma gondii

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CYTOKINE; ICOSANOID; INTERLEUKIN 12; LIPOXIN A;

ANIMAL MODEL; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; FLOW CYTOMETRY; HOST RESISTANCE; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOXOPLASMA GONDII; TOXOPLASMOSIS;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; BRAIN; CELLS, CULTURED; DISEASE SUSCEPTIBILITY; FEMALE; HYDROXYEICOSATETRAENOIC ACIDS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-12; LIPOXINS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; TOXOPLASMA; TOXOPLASMOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037020861     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20021183     Document Type: Article

References (27)

1. Shevach, E.M., J.T. Chang, and B.M. Segal. 1999. The critical role of IL-12 and the IL-12R beta 2 subunit in the generation of pathogenic autoreactive Th1 cells. Springer Semin. Immunopathol. 21:249-262.
2. Yap, G.S., and A. Sher. 1999. Cell-mediated immunity to Toxoplasma gondii: Initiation, regulation and effector function. Immunobiology. 201:240-247.
3. Gazzinelli, R.T., M. Wysocka, S. Hieny, T. Scharton-Kersten, A. Cheever, R. Kuhn, W. Muller, G. Trinchieri, and A. Sher. 1996. In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. J. Immunol. 157:798-805.
4. Suzuki, Y., A. Sher, G. Yap, D. Park, L.E. Neyer, O. Liesenfeld, M. Fort, H. Kang, and E. Gufwoli. 2000. IL-10 is required for prevention of necrosis in the small intestine and mortality in both genetically resistant BALB/c and susceptible C57BL/6 mice following peroral infection with Toxoplasma gondii. J. Immunol. 164:5375-5382.
5. Hoffmann, K.F., A.W. Cheever, and T.A. Wynn. 2000. IL-10 and the dangers of immune polarization: Excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis. J. Immunol. 164:6406-6416.
6. Deckert, M., S. Soltek, G. Geginat, S. Lutjen, M. Montesinos-Rongen, H. Hof, and D. Schluter. 2001. Endogenous interleukin-10 is required for prevention of a hyperinflammatory intracerebral immune response in Listeria monocytogenes meningoencephalitis. Infect. Immun. 69:4561-4571.
7. Silva, R.A., and R. Appelberg. 2001. Blocking the receptor for interleukin 10 protects mice from lethal listeriosis. Antimicrob. Agents Chemother. 45:1312-1314.
8. Aliberti, J., C. Reis e Sousa, M. Schito, S. Hieny, T. Wells, G.B. Huffnagle, and A. Sher. 2000. CCR5 provides a signal for microbial induced production of IL-12 by CD8 alpha+ dendritic cells. Nat. Immunol. 1:83-87.
9. Reis e Sousa, C., G. Yap, O. Schulz, N. Rogers, M. Schito, J. Aliberti, S. Hieny, and A. Sher. 1999. Paralysis of dendritic cell IL-12 production by microbial products prevents infection-induced immunopathology. Immunity. 11:637-647.
10. Aliberti, J., S. Hieny, C. Reis e Sousa, C.N. Serhan, and A. Sher. 2002. Lipoxin-mediated inhibition of IL-12 production by DCs: A mechanism for regulation of microbial immunity. Nat. Immunol. 3:76-82.
11. Scharton-Kersten, T.M., G. Yap, J. Magram, and A. Sher. 1997. Inducible nitric oxide is essential for host control of persistent but not acute infection with the intracellular pathogen Toxoplasma gondii. J. Exp. Med. 185:1261-1273.
12. Serhan, C.N., J.F. Maddox, N.A. Petasis, I. Akritopoulou-Zanze, A. Papayianni, H.R. Brady, S.P. Colgan, and J.L. Madara. 1995. Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry. 34:14609-14615.
13. Levy, B.D., S. Bertram, H.H. Tai, E. Israel, A. Fischer, J.M. Drazen, and C.N. Serhan. 1993. Agonist-induced lipoxin A4 generation: Detection by a novel lipoxin A4-ELISA. Lipids. 28:1047-1053.
14. Yap, G., M. Pesin, and A. Sher. 2000. Cutting edge: IL-12 is required for the maintenance of IFN-gamma production in T cells mediating chronic resistance to the intracellular pathogen, Toxoplasma gondii. J. Immunol. 165:628-631.
15. Reichmann, G., E.N. Villegas, L. Craig, R. Peach, and C.A. Hunter. 1999. The CD28/B7 interaction is not required for resistance to Toxoplasma gondii in the brain but contributes to the development of immunopathology. J. Immunol. 163: 3354-3362.
16. Braun, M.C., and B.L. Kelsall. 2001. Regulation of interleukin-12 production by G-protein-coupled receptors. Microbes Infect. 3:99-107.
17. Serhan, C.N., M. Hamberg, and B. Samuelsson. 1984. Lipoxins: Novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc. Natl. Acad. Sci. USA. 81:5335-5339.
18. Serhan, C.N. 1994. Lipoxin biosynthesis and its impact in inflammatory and vascular events. Biochim. Biophys. Acta. 1212: 1-25.
19. Ramstedt, U., C.N. Serhan, K.C. Nicolaou, S.E. Webber, H. Wigzell, and B. Samuelsson. 1987. Lipoxin A-induced inhibition of human natural killer cell cytotoxicity: Studies on stereospecificity of inhibition and mode of action. J. Immunol. 138:266-270.
20. Pouliot, M., and C.N. Serhan. 1999. Lipoxin A4 and aspirintriggered 15-epi-LXA4 inhibit tumor necrosis factor-alpha-initiated neutrophil responses and trafficking: Novel regulators of a cytokine-chemokine axis relevant to periodontal diseases. J. Periodontal Res. 34:370-373.
21. Gewirtz, A.T., B. McCormick, A.S. Neish, N.A. Petasis, K. Gronert, C.N. Serhan, and J.L. Madara. 1998. Pathogen-induced chemokine secretion from model intestinal epithelium is inhibited by lipoxin A4 analogs. J. Clin. Invest. 101: 1860-1869.
22. Bandeira-Melo, C., P.T. Bozza, B.L. Diaz, R.S. Cordeiro, P.J. Jose, M.A. Martins, and C.N. Serhan. 2000. Cutting edge: Lipoxin (LX) A4 and aspirin-triggered 15-epi-LXA4 block allergen-induced eosinophil trafficking. J. Immunol. 164:2267-2271.
23. Clish, C.B., J.A. O'Brien, K. Gronert, G.L. Stahl, N.A. Petasis, and C.N. Serhan. 1999. Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc. Natl. Acad. Sci. USA. 96:8247-8252.
24. Fiore, S., and C.N. Serhan. 1995. Lipoxin A4 receptor activation is distinct from that of the formyl peptide receptor in myeloid cells: Inhibition of CD11/18 expression by lipoxin A4-lipoxin A4 receptor interaction. Biochemistry. 34:16678-16686.
25. Scalia, R., J. Gefen, N.A. Petasis, C.N. Serhan, and A.M. Lefer. 1997. Lipoxin A4 stable analogs inhibit leukocyte rolling and adherence in the rat mesenteric microvasculature: Role of P-selectin. Proc. Natl. Acad. Sci. USA. 94:9967-9972.
26. Deng, X., H. Ueda, S.B. Su, W. Gong, N.M. Dunlop, J.L. Gao, P.M. Murphy, and J.M. Wang. 1999. A synthetic peptide derived from human immunodeficiency virus type 1 gp120 downregulates the expression and function of chemokine receptors CCR5 and CXCR4 in monocytes by activating the 7-transmembrane G-protein-coupled receptor FPRL1/LXA4R. Blood. 94:1165-1173.
27. Gewirtz, A.T., L.S. Collier-Hyams, A.N. Young, T. Kucharzik, W.J. Guilford, J.F. Parkinson, I.R. Williams, A.S. Neish, and J.L. Madara. 2002. Lipoxin a4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J. Immunol. 168:5260-5267.